Patent Docs: No New Abbott Medicines for Thailand

Disclaimer

"Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

March 14, 2007

No New Abbott Medicines for Thailand

By Jason Derry ---

Abbott Laboratories has announced that it will no longer launch new medicines in Thailand. In addition, Abbott has decided to withdraw its current applications for medicines in Thailand. The decision is based on Thailand's recent decision to issue compulsory licenses for Abbott's AIDS drug Kaletra, and the failure to reach an agreement with the Thailand government regarding reduced pricing for Kaletra. International pharmaceutical companies have openly criticized Thailand's issuance of recent compulsory licenses for two drugs (Abbott's Kaletra and Plavix made by Bristol-Myers Squibb and Sanofi-Aventis) without first consulting the companies that owned the drugs. On the other side of the issue, activists have been praising Thailand's actions while criticizing Abbott's decision as socially irresponsible.

Additional information concerning the issue of compulsory licensing in Thailand can be found in the following Patent Docs reports: